SMAD4 and colorectal carcinoma: Future research should focus on developing and validating small molecule inhibitors that activate the SMAD4 pathway, as well as the clinical efficacy of combining these inhibitors with existing immune checkpoint inhibitors, providing new hope for personalized and precision treatment and prognosis of CRC patients.